scholarly article | Q13442814 |
P356 | DOI | 10.1182/BLOOD-2006-05-020784 |
P698 | PubMed publication ID | 16985174 |
P50 | author | Reinhard Schneppenheim | Q40927877 |
Jeroen C J Eikenboom | Q42337451 | ||
Anne C Goodeve | Q42337454 | ||
Javier Batlle | Q58303365 | ||
Mohammad Hashemi Soteh | Q80292490 | ||
P2093 | author name string | Dominique Meyer | |
Francesco Rodeghiero | |||
Ulrich Budde | |||
Lars Holmberg | |||
Stefan Lethagen | |||
Giancarlo Castaman | |||
Augusto B Federici | |||
Claudine Mazurier | |||
Jenny Goudemand | |||
David Habart | |||
Will Lester | |||
John Pasi | |||
Christer Hallden | |||
Frank Hill | |||
Andrea Guilliatt | |||
Luciano Baronciani | |||
Jorgen Ingerslev | |||
Ian Peake | |||
Zdena Vorlova | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | phenotype | Q104053 |
P304 | page(s) | 112-121 | |
P577 | publication date | 2006-09-19 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) | |
P478 | volume | 109 |
Q36822738 | A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture |
Q34909055 | A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease |
Q30578631 | A variational Bayes discrete mixture test for rare variant association |
Q47350762 | Advances in the diagnosis and treatment of Von Willebrand disease |
Q49989077 | Advances in the diagnosis and treatment of Von Willebrand disease. |
Q39143793 | An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets. |
Q83025477 | Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized |
Q37175593 | Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications. |
Q39420582 | Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation |
Q92273594 | Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center |
Q36743353 | Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells |
Q36369902 | Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease |
Q30535420 | Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes |
Q45868176 | Clinical and laboratory phenotype variability in type 2M von Willebrand disease |
Q36920462 | Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States |
Q43137286 | Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease |
Q37552712 | Clinical features and types of von Willebrand disease in women with menorrhagia referred to hematology clinic of kermanshah |
Q34873778 | Clinical utility gene card for: von Willebrand disease |
Q37367262 | Collagen binding provides a sensitive screen for variant von Willebrand disease |
Q30411744 | Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project |
Q57094753 | Common sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD |
Q37259155 | Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease |
Q30555005 | Critical von Willebrand factor A1 domain residues influence type VI collagen binding |
Q41620644 | Current and Emerging Options for the Management of Inherited von Willebrand Disease. |
Q90670328 | Current approaches to diagnostic testing in von Willebrand Disease |
Q26796446 | Current controversies in the diagnosis and management of von Willebrand disease |
Q57095004 | Current issues in diagnosis and treatment of von Willebrand disease |
Q39027896 | Diagnosing von Willebrand disease: genetic analysis |
Q33608224 | Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders |
Q35220634 | Diagnostic approach to von Willebrand disease |
Q34336631 | Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients. |
Q34792758 | Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions |
Q47416217 | Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels |
Q82541258 | Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease |
Q42664083 | Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L. |
Q34310576 | Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. |
Q34667787 | Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. |
Q93092084 | Genetic Variation in the von Willebrand Factor Gene in Swedish von Willebrand Disease Patients |
Q37349860 | Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage |
Q91675224 | Genetic regulation of plasma von Willebrand factor levels in health and disease |
Q34663589 | Genetic sequence analysis of inherited bleeding diseases |
Q37351431 | Genome-wide association studies identify genetic loci for low von Willebrand factor levels |
Q93196766 | How I manage severe von Willebrand disease |
Q26738507 | Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A |
Q35859255 | Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease |
Q50965737 | Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. |
Q90665235 | Identification of a missense mutation (p.Leu1733Pro) in the A3 domain of von Willebrand factor in a family with type 2M von Willebrand disease |
Q36658007 | Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). |
Q99631229 | Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution |
Q41808379 | Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease |
Q34750409 | Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis |
Q37576572 | Laboratory testing for von Willebrand disease: toward a mechanism-based classification |
Q97551370 | Low VWF: insights into pathogenesis, diagnosis, and clinical management |
Q30433859 | Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice |
Q93035730 | Molecular Genetics of von Willebrand Disease in Korean Patients: Novel Variants and Limited Diagnostic Utility of Multiplex Ligation-Dependent Probe Amplification Analyses |
Q47165791 | Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. |
Q37602557 | Molecular testing for disorders of hemostasis |
Q36417697 | New insights into genotype and phenotype of VWD. |
Q39027900 | New treatment approaches to von Willebrand disease. |
Q36814657 | No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation |
Q47793791 | Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels |
Q86199659 | Optimization of the automated, CS-2000i™ method for measuring low levels of von Willebrand factor ristocetin cofactor activity (VWF:RCo) |
Q34923853 | Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models |
Q37703427 | Perils, problems, and progress in laboratory diagnosis of von Willebrand disease |
Q38414457 | Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging |
Q42337433 | Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort |
Q35536246 | Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies |
Q36805813 | Principles of care for the diagnosis and treatment of von Willebrand disease |
Q37119655 | Prophylaxis of bleeding episodes in patients with von Willebrand's disease |
Q35006603 | Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency |
Q28607764 | Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF |
Q34439244 | Rare platelet GPCR variants: what can we learn? |
Q36944968 | Report on von Willebrand Disease in Malaysia |
Q55431354 | Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. |
Q45871569 | The Association of Aging With Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease. |
Q28830861 | The European Hematology Association Roadmap for European Hematology Research: a consensus document |
Q37078876 | The Role of Bleeding History and Clinical Markers for the Correct Diagnosis of VWD |
Q34816051 | The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology |
Q37524379 | The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles |
Q26996413 | The molecular characterization of von Willebrand disease: good in parts |
Q37193881 | The molecular genetics of von Willebrand disease |
Q41919816 | The role of exon 45 and 16 in the pathogenesis of Von Willebrand disease in Iranian Patients |
Q34185963 | Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report. |
Q37602563 | Translational medicine advances in von Willebrand disease |
Q35849223 | VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population |
Q42937413 | VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease |
Q37253917 | Von Willebrand disease in the United States: a perspective from Wisconsin |
Q58781583 | Von Willebrand disease in the elderly: clinical perspectives |
Q30240214 | What have we learned from large population studies of von Willebrand disease? |
Q85963378 | [The research progress of Von Willebrand disease] |
Q55053921 | von Willebrand disease. |
Q37635167 | von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy |
Q26863636 | von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies |
Q36143225 | von Willebrand factor propeptide: biology and clinical utility |
Q37376222 | von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. |
Search more.